Premium
Molecular cloning and immunogenicity of renal cell carcinoma‐associated antigen G250
Author(s) -
Grabmaier Karin,
Vissers Joost L.M.,
De Weijert Mirjam C.A.,
OosterwijkWakka Jeannette C.,
Van Bokhoven Adrie,
Brakenhoff Ruud H.,
Noessner Elfriede,
Mulders Peter A.,
Merkx Gerard,
Figdor Carl G.,
Adema Gosse J.,
Oosterwijk Egbert
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(20000315)85:6<865::aid-ijc21>3.0.co;2-q
Subject(s) - immunogenicity , antigen , renal cell carcinoma , biology , cancer research , antibody , microbiology and biotechnology , complementary dna , expression cloning , gene , immunology , pathology , medicine , genetics
The molecular cloning of the cDNA and gene encoding the renal cell carcinoma (RCC)‐associated protein G250 is described. This protein is one of the best markers for clear cell RCC: all clear‐cell RCC express this protein, whereas no expression can be detected in normal kidney and most other normal tissue. Antibody studies have indicated that this molecule might serve as a therapeutic target. In view of the induction/up‐regulation of G250 antigen in RCC, its restricted tissue expression and its possible role in therapy, we set out to molecularly define the G250 antigen, which we identified as a transmembrane protein identical to the tumor‐associated antigen MN/CAIX. We determined, by FISH analysis, that the G250/MN/ CAIX gene is located on chromosome 9p12‐13. In view of the relative immunogenicity of RCC, we investigated whether the G250 antigen can be recognized by TIL derived from RCC patients. The initial characterization of 18 different TIL cultures suggests that anti‐G250 reactivity is rare. Int. J. Cancer 85:865–870, 2000. © 2000 Wiley‐Liss, Inc.